Hasil untuk "Dermatology"

J. Bos, M. Meinardi

V. Sibaud

H. Williams, P. Burney, A. Pembroke et al.

S. Swetter, H. Tsao, C. Bichakjian et al.

The incidence of primary cutaneous melanoma continues to increase each year. Melanoma accounts for the majority of skin cancer-related deaths, but treatment is usually curative following early detection of disease. In this American Academy of Dermatology clinical practice guideline, updated treatment recommendations are provided for patients with primary cutaneous melanoma (American Joint Committee on Cancer stages 0-IIC and pathologic stage III by virtue of a positive sentinel lymph node biopsy). Biopsy techniques for a lesion that is clinically suggestive of melanoma are reviewed, as are recommendations for the histopathologic interpretation of cutaneous melanoma. The use of laboratory, molecular, and imaging tests is examined in the initial work-up of patients with newly diagnosed melanoma and for follow-up of asymptomatic patients. With regard to treatment of primary cutaneous melanoma, recommendations for surgical margins and the concepts of staged excision (including Mohs micrographic surgery) and nonsurgical treatments for melanoma in situ, lentigo maligna type (including topical imiquimod and radiation therapy), are updated. The role of sentinel lymph node biopsy as a staging technique for cutaneous melanoma is described, with recommendations for its use in clinical practice. Finally, current data regarding pregnancy and melanoma, genetic testing for familial melanoma, and management of dermatologic toxicities related to novel targeted agents and immunotherapies for patients with advanced disease are summarized.

W. Aberer, A. Bircher, A. Romano et al.

A. Marzano, G. Genovese, G. Fabbrocini et al.

Please cite this article as: Marzano AV, Genovese G, Fabbrocini G, Pigatto P, Monfrecola G, Piraccini BM, Veraldi S, Rubegni P, Cusini M, Caputo V, Rongioletti F, Berti E, Calzavara-Pinton P, Varicellalike exanthem as a specific COVID-19-associated skin manifestation: multicenter case series of 22 patients, Journal of the American Academy of Dermatology (2020), doi: https://doi.org/10.1016/ j.jaad.2020.04.044.

H. Lim, S. Collins, J. Resneck et al.

A. Nast, B. Dréno, V. Bettoli et al.

R. Willemze, E. Hodak, P. Zinzani et al.

R. Willemze1, E. Hodak2, P. L. Zinzani3, L. Specht4 & M. Ladetto5, on behalf of the ESMO Guidelines Working Group* Department of Dermatology, Leiden University Medical Centre, Leiden, The Netherlands; Department of Dermatology, Rabin Medical Centre, Beilinson Hospital, Petach Tikva, Israel; Institute of Haematology and Medical Oncology, University of Bologna, Bologna, Italy; Department of Oncology and Haematology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy,

M. Fonder, G. Lazarus, D. Cowan et al.

L. Morton, T. Phillips

S. Schneider, M. L. Council

The novel coronavirus (SARS-CoV-2) pandemic has necessitated a dramatic shift in how our dermatology residents and fellows are educated. Distance or online learning has become the norm, and several national and international academic societies have combined resources to assure that continuing medical education occurs during this difficult time. The purpose of this communication is to review select online resources available to dermatology trainees and to encourage our colleagues to continue to advance our specialty through distance learning.

D. Murrell, Sandra Peña

BACKGROUND Several European countries recently developed international diagnostic and management guidelines for pemphigus, which have been instrumental in the standardization of pemphigus management, OBJECTIVE: We now present results from a subsequent Delphi consensus to broaden the generalizability of recommendations. METHODS A preliminary survey, based on the European Dermatology Forum (EDF) and the European Academy of Dermatology and Venereology (EADV) guidelines, was sent to a panel of international experts to determine the level of consensus. The results were discussed at the International Bullous Diseases Consensus Group in March 2016 during the annual American Academy of Dermatology (AAD) conference. A second survey was sent following the meeting to more experts to achieve greater international consensus. RESULTS The 39 experts participated in the first round of the Delphi-survey while 54 from 21 countries completed the second round. The number of statements in the survey was reduced from 175 topics in Delphi I to 24 topics in Delphi II based on Delphi results and meeting discussion. LIMITATIONS Each recommendation represents the majority opinion and therefore may not reflect all possible treatment options available. CONCLUSIONS We present here the recommendations resulting from this Delphi process. This international consensus includes intravenous CD20 inhibitors as a first line therapy option for moderate to severe pemphigus.

A. Nast, P. Gisondi, A. Ormerod et al.

T. Zuberbier, W. Aberer, R. Asero et al.

This guideline is the result of a systematic literature review using the ‘Grading of Recommendations Assessment, Development and Evaluation’ (GRADE) methodology and a structured consensus conference held on 28 and 29 November 2012, in Berlin. It is a joint initiative of the Dermatology Section of the European Academy of Allergy and Clinical Immunology (EAACI), the EU-funded network of excellence, the Global Allergy and Asthma European Network (GA 2 LEN), the European Dermatology Forum (EDF), and the World Allergy Organization (WAO) with the participation of delegates of 21 national and international societies. Urticaria is a frequent, mast cell-driven disease, presenting with wheals, angioedema, or both. The life-time prevalence for acute urticaria is approximately 20%. Chronic spontaneous urticaria and other chronic forms of urticaria do not only cause a decrease in quality of life, but also affect performance at work and school and, as such, are members of the group of severe allergic diseases. This guideline covers the definition and classification of urticaria, taking into account the recent progress in identifying its causes, eliciting factors and pathomecha

D. Veale, Lucinda J. Gledhill, P. Christodoulou et al.

A. Nast, B. Dréno, V. Bettoli et al.

T. Zuberbier, R. Asero, C. Bindslev‐Jensen et al.

Alexandra Metsini, Linda Ryen, Scott Montgomery et al.

Atopic dermatitis (AD) is a chronic skin disease associated with impaired quality of life. Evidence from Sweden on out-of-pocket expenses and productivity losses remains limited. This study assessed the burden of AD among adults in relation to health-related quality of life (HRQoL), work productivity, activity impairment, willingness to pay for symptom relief, economic outcomes, considering comorbid asthma, allergies, depression and anxiety. A cross-sectional survey was conducted between 2024 and 2025 among 220 members of the Swedish Asthma and Allergy Patient Association. Validated instruments included the Dermatology Life Quality Index (DLQI), EuroQol five-dimensions, five-levels instrument (EQ-5D-5L), Patient Benefit Index, and Work Productivity and Activity Impairment questionnaire. Descriptive and regression analyses were performed. Respondents (89.8% female; mean age 43 years) reported moderate HRQoL impairment (mean DLQI 10.1). DLQI and EQ-5D-5L were worse among those with allergic or non-atopic comorbidities but did not differ by asthma status. Mean annual out-of-pocket costs and productivity losses were €900 (95% CI: 401.1–1,758.4) and €1,972 (95% CI: 1,198.7–2,828.0), respectively. Itch intensity and activity impairment were associated with lower HRQoL and higher costs. AD is related to worsened work and activity functioning and high economic burden, suggesting the need for improved support and management strategies for affected adults.

W. Meijden, M. Boffa, B. Harmsel et al.

2021 European guideline for the management of vulval conditions W.I. van der Meijden, M.J Boffa, B. ter Harmsel, G. Kirtschig, F. Lewis, M. Moyal-Barracco, G.-S. Tiplica, J. Sherrard Department of Dermatology, Betsi Cadwaladr University Health Board, Bangor, UK Department of Dermatology, Mater Dei Hospital, Msida, Malta Department of Gynaecology, Roosevelt kliniek, Leiden, The Netherlands Gesundheitszentrum Frauenfeld, Frauenfeld, Switzerland St John’s Institute of Dermatology, Guy’s and St Thomas’ Hospital, London, UK Department of Dermatology, Tarnier-Cochin Hospital, Paris, France Dermatology 2, Colentina Clinical Hospital, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania Department of Sexual Health, Wycombe General Hospital, Bucks, UK *Correspondence: J. Sherrard. E-mail: jackie.sherrard@nhs.net Received: 6 December 2021; Accepted: 14 March 2022